This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Tue, 06/11/2024 - 18:09 June 11, 2024 — Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced that Hospital Santa Maria della Pietà, in Nola in the Metropolitan City of Naples, has established the first robotic cardiac heart program in Southern Italy.
milla1cf Thu, 05/30/2024 - 10:31 May 30, 2024 — Stereotaxis , a pioneer in surgical robotics for minimally invasive endovascular intervention, announced the successful treatment of the first heartrhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
As a result, healthcare faces rising expenses from frequent emergency room visits, lengthy hospital stays, costly procedures like stent placements and bypass surgeries, as well as the long-term management of chronic conditions like heartfailure (HF). These costs represent a massive portion of total health expenditures.
Four heartrhythm organizations from around the globe developed the statement. It is also published in HeartRhythm , the official journal of the HRS, Journal of Arrhythmia , the official journal of the APHRS, and Journal of Interventional Cardiac Electrophysiology , the official journal of the LAHRS.
Abstract Patients presenting with or alerting emergency networks due to acute heartfailure (AHF) form a diverse group with a plethora of symptoms, risks, comorbidities, and aetiologies. New VAs during AHF have previously identified patients with higher in-hospital and 60-day morbidity and mortality.
a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of HeartFailure. The manuscript is available online at the European Journal of HeartFailure website.
The findings were presented during the final day of the HeartRhythm Society meeting, HRS 2024. have heartfailure, and the prevalence is expected to rise to 8.5 1 Additionally, more than 30% of heartfailure patients have conduction abnormalities. Approximately 6.7 million adults in the U.S.
1,2 People living with AFib face an increased risk of stroke, heartfailure and death, and many rely on cardiac ablation to treat the condition effectively. Helmut Puererfellner at Ordensklinikum hospital in Linz, Austria; Prof. Roland Tilz at the University Heart Center in Luebeck, Germany; Prof.
The robotic technology represented an entirely novel way to address heartrhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. When left untreated, arrhythmias may significantly increase the risk of stroke, heartfailure, and sudden cardiac arrest.
Cardioversion is used to correct abnormal heartrhythms, also known as arrhythmias. When your heart beats too quickly, too slow, or irregularly, it can affect your blood flow and lead to severe complications like stroke or heartfailure. Cardioversions can help “reset” your heartrhythm to its regular pattern.
As we all know, early diagnosis of such diseases is crucial in order to prevent patients from suffering heartfailure or sudden death. The most traditional and the most common method for detecting heartrhythm abnormalities is manual Holter ECG analysis. This is why time is so important. first appeared on Cardiomatics.
All About Cardiac Remote Patient Monitoring Software Comprehensive healthcare for rhythm, heartfailure, and hypertension requires the ability to monitor a heart’s condition. Cardiac implantable devices are sophisticated technology that provide both therapy and diagnostics for patients with irregular heartrhythms.
Atrial fibrillation, or AFib, is the most common type of heartrhythm disorder (arrhythmia), affecting over 6 million Americans, and the number is expected to double by 2030. If untreated, AFib can lead to or exacerbate heartfailure, and it significantly increases a person’s risk of stroke.
The Beginning: The Need for Cardiac Remote Patient Monitoring The first implantable pacemaker, was developed in the late 1950s, but the first clinically successful pacemaker was implanted into a 77-year-old at a Veterans Affairs hospital in New York in 1960.
Maron, MD , a cardiologist and director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital and Medical Center in Burlington, Massachusetts, and the study’s lead author. The safety and tolerability of the drug in this phase 2 trial was excellent. These data strongly support moving on to phase 3 development.”
Yakubu Bene-Alhasan, MD milla1cf Tue, 04/02/2024 - 12:14 April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heartfailure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heartfailure.
Similar clinical outcomes were observed among men and women undergoing left bundle branch area pacing (LBBAP) for CRT, and men undergoing LBBAP had a lower risk of heartfailure (HF)-related hospitalizations and all-cause mortality when compared to men undergoing biventricular pacing (BIVP), according to a study presented at HeartRhythm 2024 and simultaneously (..)
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content